DLTH:NASDAQDuluth Holdings Inc. Analysis
Data as of 2026-06-12 - not real-time
$4.68
Latest Price
8/10Risk
Risk Level: High
Executive Summary
DLTH is trading at $4.68, comfortably above its 20‑day SMA of $3.70 and its 50‑day SMA of $3.46, indicating short‑term bullish momentum. The 200‑day SMA sits near $2.98, further confirming a longer‑term uptrend. The MACD line sits at +0.34 above the signal line (+0.20), producing a bullish histogram (+0.14). However, the 14‑day RSI has climbed to 71, placing the stock in overbought territory. Volume has been trending upward, supporting the price advance. The equity exhibits a high 30‑day volatility of roughly 94% and a beta of 1.85, suggesting pronounced price swings relative to the market. The fear‑greed index reads “Extreme Greed,” reflecting strong investor appetite despite the risk profile.
On the fundamentals side, the company posted a narrowed Q1 loss, with gross margin expanding to 57.4% and adjusted EBITDA turning positive at $2.6 M. Free cash flow of $61.7 M and operating cash flow of $67.2 M provide a cushion against the $148 M debt load, though the debt‑to‑equity ratio remains elevated at ~95%. Earnings per share remain negative, and the forward P/E is –133, underscoring ongoing profitability challenges. The discounted cash‑flow model estimates a fair value of $17.73, implying a potential upside of over 200% versus the current price. Management’s plan to double EBITDA by FY2028 and to re‑energize the brand adds a growth narrative that could bridge the valuation gap.
On the fundamentals side, the company posted a narrowed Q1 loss, with gross margin expanding to 57.4% and adjusted EBITDA turning positive at $2.6 M. Free cash flow of $61.7 M and operating cash flow of $67.2 M provide a cushion against the $148 M debt load, though the debt‑to‑equity ratio remains elevated at ~95%. Earnings per share remain negative, and the forward P/E is –133, underscoring ongoing profitability challenges. The discounted cash‑flow model estimates a fair value of $17.73, implying a potential upside of over 200% versus the current price. Management’s plan to double EBITDA by FY2028 and to re‑energize the brand adds a growth narrative that could bridge the valuation gap.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI overbought at 71
- Bullish MACD and SMA alignment
- High volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Gross margin expansion to 57.4%
- Positive free cash flow covering debt
- DCF fair value indicating large upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic plan to double EBITDA by FY2028
- Undervalued relative to intrinsic value
- Sustainable cash generation despite earnings losses
Key Metrics & Analysis
Financial Health
Revenue Growth-4.00%
Profit Margin-1.99%
P/E Ratio-133.7
ROE-6.86%
ROA-0.34%
Debt/Equity94.96
P/B Ratio1.0
Op. Cash Flow$67.2M
Free Cash Flow$61.7M
Technical Analysis
TrendBullish
RSI71.5
Support$2.96
Resistance$5.08
MA 20$3.70
MA 50$3.46
MA 200$2.98
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$17.73
Target Price$5.00
Upside/Downside6.84%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.85
Volatility94.46%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.